Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Parallel Group, Double Blind, Vehicle-controlled Study of the Efficacy and Safety of Roflumilast Foam 0.3% (ZORYVE®) in Trial Participants With Seborrheic Dermatitis

NCT07683806 is registered in ClinicalTrials.gov with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07683806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07683806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Parallel Group, Double Blind, Vehicle-controlled Study of the Efficacy and Safety of Roflumilast Foam 0.3% (ZORYVE®) in Trial Participants With Seborrheic Dermatitis
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 24, 2026
Completion date
August 3, 2027
Enrollment
309 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

seborrheic dermatitis